This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Masimo SafetyNet to Help Clinicians Fight Coronavirus Better
by Zacks Equity Research
Masimo (MASI) announces the full market release of Masimo SafetyNet, which is a remote patient management solution that will help in the fight against the COVID-19 pandemic.
The Zacks Analyst Blog Highlights: A10 Networks, Chemed, Core-Mark, Eli Lilly and Masimo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: A10 Networks, Chemed, Core-Mark, Eli Lilly and Masimo
AngioDyanamics (ANGO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) fiscal third-quarter results benefit from strong growth across all businesses and higher revenues.
5 Stocks With Recent Price Strength Amid Coronavirus Logjam
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
5 Low-Risk Stocks to Buy for Epic Price Swings Since 1929
by Tirthankar Chakraborty
The S&P 500's average daily percentage price change over the past five weeks has been plus or minus 4.8%. This explains why the Cboe Volatility Index remains elevated at around the 40s.
Nevro (NVRO) Looks Good: Stock Adds 6.5% in Session
by Zacks Equity Research
Nevro (NVRO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MASI) Outperforming Other Medical Stocks This Year?
Here's Why Investors Should Buy Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) sees a slew of developments lately.
Masimo & University Hospitals Unite for Patient Monitoring
by Zacks Equity Research
Masimo (MASI) sees a plethora of developments lately.
Why Is Masimo (MASI) Down 9.6% Since Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Masimo's Latest Buyout to Boost Respiratory Product Spectrum
by Zacks Equity Research
Masimo (MASI) expects the transaction to be neutral to 2020 earnings.
4 MedTech Stocks to Scoop Up Amid the Coronavirus Crisis
by Debanjana Dey
Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.
Has Masimo (MASI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MASI) Outperforming Other Medical Stocks This Year?
Masimo Inks Deal With Imprivata, Improves Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) partnership with Imprivata is likely to boost patient outcomes through the integration of Imprivata Medical Device Access into Masimo's Hospital Automation solutions.
Masimo (MASI) Gets FDA Nod for RRp Monitoring Technology
by Zacks Equity Research
The FDA clearance of this monitoring system is expected to strengthen Masimo's (MASI) portfolio of pulse oximetry technologies.
Masimo (MASI) Q4 Earnings Beat Estimates, View Impressive
by Zacks Equity Research
Masimo (MASI) sees expansion in gross and operating margin in Q4.
COPD Devices Gain Regulatory Go-Ahead: 3 Stocks in Focus
by Sriparna Ghosal
Growth in the COPD devices market can be attributed to factors like steadily rising geriatric population, increasing incidence of smoking and chronic respiratory diseases.
Masimo Posts Solid Preliminary 2019 Results, Issues Guidance
by Zacks Equity Research
Higher revenues and upbeat 2020 outlook benefit Masimo's (MASI) preliminary full-year 2019 results.
Masimo's Neonatal RD SET Pulse Oximetry Sensors Get FDA Nod
by Zacks Equity Research
Masimo (MASI) will cater to the whole prenatal patient population, with the recent FDA clearance within the SET pulse oximetry business.
Here's Why You Should Hold on to Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) raises revenue and earnings guidance for 2019.
Masimo (MASI) Expands Partnership with Texas-Based Drager
by Zacks Equity Research
Masimo (MASI) sees a slew of developments in recent times.
Digital Health Gaining Momentum: 3 MedTech Stocks in Focus
by Trina Mukherjee
Digital health is committed to changing the face of healthcare as evident from its innovative solutions for the betterment of patients' lives.
Here's Why You Should Hold on to Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) raises 2019 revenue and EPS guidance.
Masimo (MASI) Earnings Beat Estimates in Q3, View Raised
by Zacks Equity Research
Masimo (MASI) raises its 2019 product revenue guidance.
Masimo (MASI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 7.04% and 3.69%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?